AI Case Studies in Discovery & Clinical Development

Biopharmas can use code BIOPHARMA100 to register for free.

10:30-11:00am -
Target Identification, Validation & Molecule Generation

Martin Akerman, CTO, Envisagenics
Spyro Mousses, CEO, Systems Oncology


11:00 - 11:30am
How to Approach Predictive ADMET Modeling and Maximize its Impact on Drug Discovery Projects
• Retrospective analysis of results in ADMET
• The importance of culture – getting the chemistry teams in the right mindset, using the advanced AI/ML technologies, and willing to incorporate the predictions and move ahead using models – use cases
• ADMET models and technologies are better so what’s the future for solving the potency and selectivity challenges?

Barun Bhhatarai, Investigator, Novartis Institutes for BioMedical Research (NIBR)
Marcel Hop, Vice President, Drug Metabolism and Pharmacokinetics, Genentech


11:30 - 11:45
Innovation Spotlight Presentations

Rafael Rosengarten, PhD, CEO, Genialis
• Tackling the "Small Data Problem": Integration and Harmonization Strategies To Unlock the Potential of Clinical Trial Datasets

Ariel Katz, Co-Founder, H1
• Leveraging AI to Aggregate Healthcare Data and HCP Data


11:45 - 12:30
Leader Perspectives in Clinical Development: Achieving Consistency in Validating & Operationalizing the AI/ML Automation Efforts Transforming Biopharma

Although certain intelligent automation technologies have been used in some PV areas for years (e.g. rule-based software, auto-coding, auto-narrative generation, etc.), rapid development of newer technologies (e.g. machine learning, natural language processing) has outpaced some PV regulations. Therefore, continued innovation will be more likely and ultimately more successful if companies and 3rd party developers can be reasonably assured they have adequately validated their systems and automated processes.

A panel of biopharma leaders will delve into:
• IAO in the past and now – how it’s transforming our work
• Specific Intelligent Automation Opportunities in Pharmacovigilance Solutions
- Short Term - Validation Proposal
- Long Term - to Transform and Accelerate

Neal Grabowski, MEng, MBA, Director, Safety Data Science, AbbVie; Intelligent Automation Opportunities (IAO) in PV Workstream Lead, TransCelerate BioPharma, Inc.

Danielle Abatemarco, MSc, Scientific Publications Lead, WorldWide Patient Safety, Bristol-Myers Squibb; Intelligent Automation Opportunities (IAO) Workstream Member, TransCelerate BioPharma, Inc.
Andrew Bate, PhD, Head of Safety Innovation & Analytics, GSK Pharmacovigilance Steering Committee Member, TransCelerate BioPharma, Inc.


12:30 - 1:00pm
Unconventional AI/ML for the Biomedical Sciences

• Understanding driver biology and Identifying causal drug targets that are driving disease ideology
• Going after the means and the capabilities to drive more effective therapeutics with far fewer associated side effects
• Quantum computing approaches to analysis of multi-omic data

Thomas W. Chittenden, PhD, DPhil, PStat, Chief Data Science Officer, Genuity Science
  • When: Eastern Time (US & Canada)
  • Duration: 2 hours 30 minutes
  • Price: $95.00
  • Language: English
  • Who can attend? Anyone with the event link can attend
  • Dial-in available? (listen only): Not available.
  • 1592300097-dd5726b07d45ab68
  • 1593530318-81955b899ca9f79f
  • 1597397653-9497c7a67bd8f96f
  • 3
  • 1593527086-f1722a8ba317a0c3
  • 1593528268-da2450d68a5d91e0
  • 1590662571-9eb325b55c96db6c
  • D
  • 1593528318-1bc5c35d6613df40
  • N